GILD250110C96000
- 0.01
- 0.000.00%
Gilead Sciences Newsroom
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Drugs Not Selected for Medicare Price Negotiation Nearly Doubled - Report
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
S&P 500 Positive for 'First Five Days,' Huang Sees Decades till Quantum | Wall Street Today
Gilead Sciences Hits 6-week Low
Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus
Wednesday Market Falls, Quantum Computing Pulls Back Hard on Treasury Yield Crunch | Live Stock
Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40%
Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead
Express News | Corrected-Buzz-Pharma Group Galapagos Jumps 11% on Planned Split
Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today
Looking Into Gilead Sciences's Recent Short Interest
Market Sells CES Tech News, ISM Tuesday as Nvidia Champions Robots Monday | Live Stock
Gilead Sciences, Inc. (NASDAQ:GILD) Is a Favorite Amongst Institutional Investors Who Own 86%
RBC Trims Price Target on Gilead Sciences to $83 From $84, Keeps Sector Perform Rating
Hookipa Shareholder Gilead Sciences to Back Poolbeg Merger
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today
Market Climbed Monday Just Past Santa Rally High Water Mark | Wall Street Today
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development